KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Long-Term Debt Issuances (2016 - 2025)

BeOne Medicines (ONC) has disclosed Long-Term Debt Issuances for 10 consecutive years, with $26.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Issuances rose 187.2% to $26.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $911.0 million, a 9962.96% increase, with the full-year FY2025 number at $911.0 million, up 9962.96% from a year prior.
  • Long-Term Debt Issuances was $26.0 million for Q4 2025 at BeOne Medicines, down from $885.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $885.0 million in Q3 2025 to a low of -$22.5 million in Q4 2023.
  • A 5-year average of $81.2 million and a median of $9.1 million in 2024 define the central range for Long-Term Debt Issuances.
  • Peak YoY movement for Long-Term Debt Issuances: tumbled 234.5% in 2024, then skyrocketed 9875.76% in 2025.
  • BeOne Medicines' Long-Term Debt Issuances stood at $6.0 million in 2021, then surged by 520.9% to $37.4 million in 2022, then crashed by 160.21% to -$22.5 million in 2023, then surged by 140.23% to $9.1 million in 2024, then soared by 187.2% to $26.0 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Long-Term Debt Issuances are $26.0 million (Q4 2025), $885.0 million (Q3 2025), and $9.1 million (Q4 2024).